At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of ...

Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best Dividend Paying Stocks to Buy Right Now. Merck & Co., Inc.

New ASCO data boosted the case for Ivonescimab as a potential challenger to Merck's blockbuster cancer drug Keytruda. ・Phase ...

Merck reported first-quarter results that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products.  The pharmaceutical giant also narrowed its 2026 sales ...

Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was ...

TheFly reported on May 22 that MRK announced that the European Medicines Agency’s Committee for Medicinal Products for Human ...

Merck MRK boasts more than six blockbuster drugs in its portfolio, with the blockbuster PD-L1 inhibitor Keytruda being the key top-line driver. Keytruda, approved for several types of cancer, alone ...

Merck’s MRK strong foothold in the oncology space is propelled by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounted for more than 50% of the company’s ...

Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly ...

A yearlong international investigation into one of the world's most important cancer drugs shows how a medical breakthrough has also become a fault line in global health, exposing how pricing systems, ...